Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF)

Next Previous
Trial Profile

Non-Interventional Study on Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation (NVAF)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Edoxaban (Primary)
  • Indications Cardiovascular disorders; Embolism; Stroke
  • Focus Adverse reactions
  • Acronyms ETNA-AF-KOR-TWN
  • Sponsors Daiichi Sankyo Inc

    • Most Recent Events

    • 26 Oct 2022 Results of sub analysis of the Global EMIT-AF/VTE program(NCT02950168, NCT02951039) comparing the baseline characteristics, periprocedural management, and outcomes of patients who underwent major or nonmajor surgery.presented at the ANESTHESIOLOGY 2022 Annual Meeting of the American Society of Anesthesiologists
    • 11 Oct 2022 Results of a sub-group analysis from two clinical studies (NCT02950168 and NCT02951039) assessing physician-guided periprocedural management of Edoxaban therapy and clinical outcomes in patients undergoing endoscopic procedures presented at the 30th United European Gastroenterology Week
    • 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top